How Informative Are Open-Label Studies for Youth With Bipolar Disorder? A Meta-Analysis Comparing Open-Label Versus Randomized, Placebo-Controlled Clinical Trials

被引:8
作者
Biederman, Joseph [1 ,2 ]
Petty, Carter R. [1 ]
Woodworth, K. Yvonne [1 ]
Lomedico, Alexandra [1 ]
O'Connor, Katherine B. [1 ]
Wozniak, Janet [1 ,2 ]
Faraone, Stephen V. [3 ,4 ]
机构
[1] Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol & Adult, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA
[3] SUNY Upstate Med Univ, Dept Psychiat & Neurosci, Syracuse, NY USA
[4] SUNY Upstate Med Univ, Dept Physiol, Syracuse, NY USA
关键词
ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; PHARMACOLOGICAL-TREATMENT; OLANZAPINE MONOTHERAPY; DOUBLE-BLIND; CHILDREN; ADOLESCENTS; MANIA; ARIPIPRAZOLE; RISPERIDONE; DIVALPROEX;
D O I
10.4088/JCP.10m06490
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Objective: To examine the informativeness of open-label trials toward predicting results in subsequent randomized, placebo-controlled clinical trials of psychopharmacologic treatments for pediatric bipolar disorder. Data Sources: We searched journal articles through PubMed at the National Library of Medicine using bipolar disorder, mania, pharmacotherapy, treatment and clinical trial as keywords. This search was supplemented with scientific presentations at national and international scientific meetings and submitted manuscripts from our group. Study Selection: Selection criteria included (1) enrollment of children diagnosed with DSM-IV bipolar disorder; (2) prospective assessment of at least 3 weeks; (3) monotherapy of a pharmacologic treatment for bipolar disorder; (4) use of a randomized placebo-controlled design or an open-label design for the same therapeutic compound; and (5) repeated use of the Young Mania Rating Scale (YMRS) as an outcome. Data Extraction:The following information and data were extracted from 14 studies: study design, name of medication, class of medication, dose of medication, sample size, age, sex, trial length, and YMRS mean and standard deviation baseline and follow-up scores. Results: For both study designs, the pooled effect size was statistically significant (open-label studies, z=8.88, P<.001; randomized placebo-controlled studies, z=13.75, P<.001), indicating a reduction in the YMRS from baseline to endpoint in both study designs. In a meta-analysis regression, study design was not a significant predictor of mean change in the YMRS. Conclusions: We found similarities in the treatment effects between open-label and randomized placebo-controlled studies in youth with bipolar disorder indicating that open-label studies are useful predictors of the potential safety and efficacy of a given compound in the treatment of pediatric bipolar disorder. J Clin Psychiatry 2012;73(3):358-365 (C) Copyright 2011 Physicians Postgraduate Press, Inc.
引用
收藏
页码:358 / 365
页数:8
相关论文
共 28 条
[1]  
[Anonymous], 1998, Fundamentals of clinical trials
[2]   Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children [J].
Biederman, J ;
Mick, E ;
Hammerness, P ;
Harpold, T ;
Aleardi, M ;
Dougherty, M ;
Wozniak, J .
BIOLOGICAL PSYCHIATRY, 2005, 58 (07) :589-594
[3]   Aripiprazole in the treatment of pediatric bipolar disorder: A systematic chart review [J].
Biederman, J ;
McDonnell, MA ;
Wozniak, J ;
Spencer, T ;
Aleardi, M ;
Falzone, R ;
Mick, E .
CNS SPECTRUMS, 2005, 10 (02) :141-148
[4]   An open-label trial of risperidone in children and adolescents with bipolar disorder [J].
Biederman, J ;
Mick, E ;
Wozniak, J ;
Aleardi, M ;
Spencer, T ;
Faraone, SV .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2005, 15 (02) :311-317
[5]   A prospective follow-up study of pediatric bipolar disorder in boys with attention-deficit/hyperactivity disorder [J].
Biederman, J ;
Mick, E ;
Faraone, SV ;
Van Patten, S ;
Burback, M ;
Wozniak, J .
JOURNAL OF AFFECTIVE DISORDERS, 2004, 82 :S17-S23
[6]   Pediatric bipolar disorder coming of age [J].
Biederman, J .
BIOLOGICAL PSYCHIATRY, 2003, 53 (11) :931-934
[7]   The naturalistic course of pharmacologic treatment of children with maniclike symptoms: A systematic chart review [J].
Biederman, J ;
Mick, E ;
Bostic, JQ ;
Prince, J ;
Daly, J ;
Wilens, TE ;
Spencer, T ;
Garcia-Jetton, J ;
Russell, R ;
Wozniak, J ;
Faraone, SV .
JOURNAL OF CLINICAL PSYCHIATRY, 1998, 59 (11) :628-637
[8]   Systematic chart review of the pharmacologic treatment of comorbid attention deficit hyperactivity disorder in youth with bipolar disorder [J].
Biederman, J ;
Mick, E ;
Prince, J ;
Bostic, JQ ;
Wilens, TE ;
Spencer, T ;
Wozniak, J ;
Faraone, SV .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 1999, 9 (04) :247-256
[9]   A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder [J].
Biederman, Joseph ;
Mick, Eric ;
Spencer, Thomas ;
Dougherty, Meghan ;
Aleardi, Megan ;
Wozniak, Janet .
BIPOLAR DISORDERS, 2007, 9 (08) :888-894
[10]   An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder [J].
Biederman, Joseph ;
Mick, Eric ;
Spencer, Thomas ;
Doyle, Robert ;
Joshi, Gagan ;
Hammerness, Paul ;
Kotarski, Megan ;
Aleardi, Megan ;
Wozniak, Janet .
CNS SPECTRUMS, 2007, 12 (09) :683-689